The viral CC chemokine-binding protein vCCI inhibits monocyte chemoattractant protein-1 activity by masking its CCR2B-binding site

被引:44
作者
Beck, CG [1 ]
Studer, C [1 ]
Zuber, JF [1 ]
Demange, BJ [1 ]
Manning, U [1 ]
Urfer, R [1 ]
机构
[1] Novartis Pharma AG, Dept Arthrit Biol, CH-4002 Basel, Switzerland
关键词
D O I
10.1074/jbc.M106305200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Monocyte chemoattractant protein-1 (MCP-1) is a chemotactic cytokine mainly acting on monocytes and T cells that elicits its biological effects by interacting with the seven-transmembrane helix receptor CCR2B. The vaccinia virus strain Lister and many other poxviruses express soluble proteins (vCCI) that bind MCP-1 and other CC chemokines and inhibit their function. In order to define the interaction site of MCP-1 with vCCI from vaccinia, surface exposed residues of MCP-1 were identified and mutated to alanine. The MCP-1 variants were expressed, purified, and their interaction with vCCI was characterized. The site on MCP-1 for vCCI binding is dominated by arginine 18 with important additional contributions from tyrosine 13 and arginine 24. These residues define a binding site that largely overlaps with the CCR2B receptor interaction site. The viral chemokine-binding protein vCCI thus inhibits the biological function of MCP-1 by directly masking its CCR2B receptor-binding site.
引用
收藏
页码:43270 / 43276
页数:7
相关论文
共 39 条
[31]   Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression [J].
Smith, MW ;
Dean, M ;
Carrington, M ;
Winkler, C ;
Huttley, GA ;
Lomb, DA ;
Goedert, JJ ;
OBrien, TR ;
Jacobson, LP ;
Kaslow, R ;
Buchbinder, S ;
Vittinghoff, E ;
Vlahov, D ;
Hoots, K ;
Hilgartner, MW ;
OBrien, SJ .
SCIENCE, 1997, 277 (5328) :959-965
[32]   Mapping of MCP-1 functional domains by peptide analysis and site-directed mutagenesis [J].
Steitz, SA ;
Hasegawa, K ;
Chiang, SL ;
Cobb, RR ;
Castro, MA ;
Lobl, TJ ;
Yamada, M ;
Lazarides, E ;
Cardarelli, PM .
FEBS LETTERS, 1998, 430 (03) :158-164
[33]   THE BINDING EPITOPES OF NEUROTROPHIN-3 TO ITS RECEPTORS TRKC AND GP75 AND THE DESIGN OF A MULTIFUNCTIONAL HUMAN NEUROTROPHIN [J].
URFER, R ;
TSOULFAS, P ;
SOPPET, D ;
ESCANDON, E ;
PARADA, LF ;
PRESTA, LG .
EMBO JOURNAL, 1994, 13 (24) :5896-5909
[34]  
WELLS JA, 1991, METHOD ENZYMOL, V202, P390
[35]   Crystal structure of nerve growth factor in complex with the ligand-binding domain of the TrkA receptor [J].
Wiesmann, C ;
Ultsch, MH ;
Bass, SH ;
de Vos, AM .
NATURE, 1999, 401 (6749) :184-188
[36]   Crystal structure at 1.7 angstrom resolution of VEGF in complex with domain 2 of the Flt-1 receptor [J].
Wiesmann, C ;
Fuh, G ;
Christinger, HW ;
Eigenbrot, C ;
Wells, JA ;
deVos, AM .
CELL, 1997, 91 (05) :695-704
[37]   PURIFICATION AND AMINO-ACID ANALYSIS OF 2 HUMAN GLIOMA-DERIVED MONOCYTE CHEMOATTRACTANTS [J].
YOSHIMURA, T ;
ROBINSON, EA ;
TANAKA, S ;
APPELLA, E ;
KURATSU, JI ;
LEONARD, EJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 169 (04) :1449-1459
[38]  
ZHANG YJ, 1994, J BIOL CHEM, V269, P15918
[39]   Chemokines: A new classification system and their role in immunity [J].
Zlotnik, A ;
Yoshie, O .
IMMUNITY, 2000, 12 (02) :121-127